Paper

Isoform switching as a mechanism of acquired resistance to isocitrate dehydrogenase inhibition

You, Daoqi, Intlekofer, Andrew M, Hou, Shengqi, Stein, Eytan M, Abou-Alfa, Ghassan K, Hyman, David M, Selcuklu, S Duygu, Frattini, Mark G, Zehir, Ahmet, Wu, Bin, Mellinghoff, Ingo K, Liu, Guowen, Lowery, Maeve A, Janjigian, Yelena Y, Shih, Alan H, Roshal, Mikhail, Macbeth, Kyle J, Fan, Bin, Levine, Ross L, Tosolini, Alessandra, Famulare, Christopher, Papaemmanuil, Elli, Tallman, Martin S, Viale, Agnes, Schvartzman, Juan M, Patel, Minal, Reznik, Ed, Harding, James J, Finley, Lydia W S, Choe, Sung, Diaz, Luis A, Do, Richard K G

2018

Overview

Somatic mutations in cytosolic or mitochondrial isoforms of isocitrate dehydrogenase (IDH1 or IDH2, respectively) contribute to oncogenesis via production of the metabolite 2-hydroxyglutarate (2HG). Isoform-selective IDH inhibitors suppress 2HG production and induce clinical responses in patients with IDH1- and IDH2-mutant malignancies. Despite the promising activity of IDH inhibitors, the mechanisms that mediate resistance to IDH inhibition are poorly understood. Here, we describe four clinical cases that identify mutant IDH isoform switching, either from mutant IDH1 to mutant IDH2 or vice versa, as a mechanism of acquired clinical resistance to IDH inhibition in solid and liquid tumors.

• Publisher: Cold Spring Harbor Laboratory Press,Cold Spring Harbor Laboratory
• Subject: Cancer Biology / Dehydrogenases / Isocitrate dehydrogenase / Isoforms / Mitochondria / Tumorigenesis / Tumors